Research programme: glaucoma therapeutics - Duska Therapeutics

Drug Profile

Research programme: glaucoma therapeutics - Duska Therapeutics

Alternative Names: Glaucoma therapeutics research programme - Duska Therapeutics

Latest Information Update: 20 Feb 2009

Price : $50

At a glance

  • Originator Duska Therapeutics
  • Class
  • Mechanism of Action Purinergic P2X7 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma

Most Recent Events

  • 21 Jun 2005 Early research in Glaucoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top